

**Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208
Particular Matter Waivers**

Name: Sean Hennessy, Pharm.D., Ph.D.

Committee: Gastrointestinal Drugs Advisory Committee

Meeting Date(s): January 23, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda item: to discuss the safety and efficacy of Entereg (alvimopan), new drug application (NDA) 21-775, Adolor Corporation, for the proposed indication of acceleration of time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis, I am eligible to receive particular matter waivers under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	Involvement	Magnitude
Unrelated Consulting	Competing Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waivers are not valid.

_____/S/_____
Signature

_____/12/14/07_____
Date